Phathom Pharmaceuticals (PHAT) Insider Trading & Ownership $7.61 +0.16 (+2.15%) (As of 05:45 PM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Phathom Pharmaceuticals (NASDAQ:PHAT) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage24.10%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$99,125.00Number OfInsiders Selling(Last 12 Months)4Amount OfInsider Selling(Last 12 Months)$30.83 M Get PHAT Insider Trade Alerts Want to know when executives and insiders are buying or selling Phathom Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address PHAT Insider Buying and Selling by Quarter Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Phathom Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails12/19/2024Azmi NabulsiCOOSell1,118$8.00$8,944.00 12/19/2024Molly HendersonCFOSell1,291$8.00$10,328.00 12/13/2024Frank KarbeDirectorBuy12,500$7.93$99,125.00 7/15/2024Azmi NabulsiCOOSell10,901$11.72$127,759.72 7/15/2024Molly HendersonCFOSell4,325$11.72$50,689.00 7/15/2024Terrie CurranInsiderSell33,848$11.72$396,698.56 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 4/8/2024Molly HendersonCFOSell3,435$11.10$38,128.50 3/22/2024Terrie CurranInsiderSell16,851$9.11$153,512.61 1/24/2024Pharmaceutical Co Ltd TakedaMajor ShareholderSell3,703,703$8.10$29,999,994.30 1/19/2024Molly HendersonCFOSell6,307$7.75$48,879.25 (Data available from 1/1/2013 forward) PHAT Insider Trading Activity - Frequently Asked Questions Who is on Phathom Pharmaceuticals's Insider Roster? The list of insiders at Phathom Pharmaceuticals includes Asit Parikh, Azmi Nabulsi, Frank Karbe, Molly Henderson, Pharmaceutical Co Ltd Takeda, and Terrie Curran. Learn more on insiders at PHAT. What percentage of Phathom Pharmaceuticals stock is owned by insiders? 24.10% of Phathom Pharmaceuticals stock is owned by insiders. Learn more on PHAT's insider holdings. Which Phathom Pharmaceuticals insiders have been buying company stock? The following insiders have purchased PHAT shares in the last 24 months: Asit Parikh ($108,740.00), Azmi Nabulsi ($82,600.00), Frank Karbe ($99,125.00), and Terrie Curran ($101,026.58). How much insider buying is happening at Phathom Pharmaceuticals? Insiders have purchased a total of 49,919 PHAT shares in the last 24 months for a total of $391,491.58 bought. Which Phathom Pharmaceuticals insiders have been selling company stock? The following insiders have sold PHAT shares in the last 24 months: Azmi Nabulsi ($136,703.72), Molly Henderson ($350,807.50), Pharmaceutical Co Ltd Takeda ($29,999,994.30), and Terrie Curran ($610,206.81). How much insider selling is happening at Phathom Pharmaceuticals? Insiders have sold a total of 3,811,069 Phathom Pharmaceuticals shares in the last 24 months for a total of $31,097,712.33 sold. Phathom Pharmaceuticals Key ExecutivesMs. Terrie J. Curran (Age 55)President, CEO & Director Compensation: $1.22M1 recent tradesMr. David A. Socks (Age 49)Co-Founder & Director Compensation: $54.17kDr. Azmi Nabulsi M.D. (Age 64)M.P.H., Co-Founder & COO Compensation: $888.9kMs. Molly Henderson CPA (Age 53)MBA, Chief Financial & Business Officer Compensation: $777.76k2 recent tradesDr. Aditya Kohli Ph.D. (Age 36)Co-Founder Compensation: $319.65kMr. Paul CocjaChief People OfficerMr. Tom HarrisChief Development Sciences OfficerDr. Eckhard Leifke M.D.Ph.D., Chief Medical OfficerMr. Martin J. GilliganChief Commercial Officer More Insider Trading Tools from MarketBeat Related Companies NewAmsterdam Pharma Insider Selling IDEAYA Biosciences Insider Selling Centessa Pharmaceuticals Insider Selling Recursion Pharmaceuticals Insider Selling ImmunityBio Insider Selling Apogee Therapeutics Insider Selling Wave Life Sciences Insider Selling Mirum Pharmaceuticals Insider Selling Akero Therapeutics Insider Selling Amphastar Pharmaceuticals Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (NASDAQ:PHAT) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
